Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).

The Cochrane Database of Systematic Reviews
Marius GoldkuhleNicole Skoetz

Abstract

Hodgkin's lymphoma (HL) is a cancer of the lymphatic system, and involves the lymph nodes, spleen and other organs such as the liver, lung, bone or bone marrow, depending on the tumour stage. With cure rates of up to 90%, HL is one of the most curable cancers worldwide. Approximately 10% of people with HL will be refractory to initial treatment or will relapse; this is more common in people with advanced stage or bulky disease. Standard of care for these people is high-dose chemotherapy and autologous stem cell transplantation (ASCT), but only 55% of participants treated with high-dose chemotherapy and ASCT are free from treatment failure at three years, with an overall survival (OS) of about 80% at three years.Checkpoint inhibitors that target the interaction of the programmed death (PD)-1 immune checkpoint receptor, and its ligands PD-L1 and PD-L2, have shown remarkable activity in a wide range of malignancies. Nivolumab is an anti-(PD)-1 monoclonal antibody and currently approved by the US Food and Drug Administration (FDA) for the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and, since 2016, for classical Hodgkin's lymphoma (cHL) after treatment with ASCT and brentuximab vedotin. To assess the ben...Continue Reading

References

Nov 19, 1992·The New England Journal of Medicine·G P CanellosB A Peterson
Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T A ListerM Tubiana
Jun 6, 1996·Health Policy·R Brooks
Mar 16, 2002·Journal of Clinical Pathology·S A PileriH Stein
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Oct 29, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R K ThomasV Diehl
May 9, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A D ZelenetzC H Moskowitz
Dec 17, 2008·Nature Reviews. Cancer·Ralf Küppers
Apr 25, 2009·The Cancer Journal·Joseph M Connors
Jul 28, 2009·Journal of Clinical Epidemiology·David MoherUNKNOWN PRISMA Group
Sep 8, 2010·The New England Journal of Medicine·Andreas EngertVolker Diehl
Sep 20, 2011·International Urogynecology Journal·Christopher M MaherCathryn M A Glazener
Jan 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bastian von TresckowAndreas Engert
Jan 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael R GreenMargaret A Shipp
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Jun 21, 2013·The Cochrane Database of Systematic Reviews·Michaela RanceaNicole Skoetz
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Jan 22, 2015·The New England Journal of Medicine·Allan H Goroll, Daniel P Hunt
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jun 25, 2015·Journal of the American Medical Informatics Association : JAMIA·Iain J MarshallByron C Wallace
Mar 5, 2016·Journal of Clinical Epidemiology·Holger J SchünemannUNKNOWN GRADE Working Group
Apr 14, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaretha G M RoemerMargaret A Shipp
May 20, 2016·Current Treatment Options in Oncology·Eri Matsuki, Anas Younes
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexander M LesokhinJohn Timmerman
Aug 9, 2016·Seminars in Hematology·Stephan MathasRalf Küppers
Oct 14, 2016·BMJ : British Medical Journal·Jonathan Ac SterneJulian Pt Higgins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Vaginosis

Bacterial vaginosis can increase the risk of sexually transmitted infections and in rare cases lead to pelvic inflammatory diseases. Discover the latest research on Bacterial Vaginosis here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.